Ovulation Induction With GnRH Analogue or Dual Trigger for Fertility Preservation in Oncological Patients

What this Trial Is About

This research aims to compare ovulation induction methods for fertility preservation in women with cancer who are about to undergo gonadotoxic therapy. It focuses on evaluating the number of eggs retrieved during oocyte cryopreservation cycles and the safety related to ovarian hyperstimulation syndrome (OHSS). The study also examines hormone levels on the day of ovulation trigger and their relationship with egg yield. Participants will receive ovulation induction using either a gonadotropin-releasing hormone analogue (GnRH-a) alone or a dual trigger combining GnRH-a with human chorionic gonadotropin (hCG). The GnRH-a is given as 0.2 mg subcutaneously, while the dual trigger group also receives 1000 to 5000 IU of urinary hCG. Treatment follows standard clinical care practices, and patients are assigned to groups based on clinical characteristics. During the study, researchers will collect data on the number of eggs retrieved, the proportion of eggs obtained compared to follicles aspirated, and the number of mature eggs shortly after retrieval. They will monitor participants for moderate OHSS within seven days post-procedure. Hormone measurements and correlations with outcomes will be assessed. Approximately 200 female patients aged 18 to 46 will be enrolled, with data collected over two years and two months.

Ovulation Induction With GnRH Analogue or Dual Trigger?